Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
GILD: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
GILD: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
GILD: third_quarter 2026 lobbying report
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp
Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV an
Public: Oct 20, 2026, 5:56 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
federal budget issues Lobbying related to pharmaceutical policy Lobbying related to pharmaceutical policy
Public: Oct 20, 2026, 2:41 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program.
Public: Oct 20, 2026, 12:49 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development.
Public: Oct 20, 2026, 12:33 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Public: Oct 20, 2026, 10:35 AM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Implementation H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing.
Public: Oct 19, 2026, 11:49 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to drug pricing Issues related to MFN pricing and trade
Public: Oct 19, 2026, 6:11 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to health policy.
Public: Oct 19, 2026, 5:20 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Domestic and global drug pricing proposals. International trade and protection of intellectual property. Global supply chain issues. Proposals to expand access to HIV treatment and prevention therapies. Coverage and reimbursement policy for Hepatitis C, HIV and cancer. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. 340B program reforms and changes.
Public: Oct 19, 2026, 11:41 AM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-
Public: Oct 18, 2026, 6:50 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to regulation of prescription drugs and biologics
Public: Oct 18, 2026, 4:58 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Public: Oct 18, 2026, 1:43 PM EDTOriginal source ↗GILD: third_quarter 2026 lobbying report
Legislative services related to corporate and international tax matters.
Public: Oct 16, 2026, 1:12 PM EDTOriginal source ↗GILD: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
GILD: Financial results
Filed 8-K for an event or period dated 2026-08-04. Financial results.
GILD: second_quarter 2026 lobbying report
federal budget issues Lobbying related to pharmaceutical policy Lobbying related to pharmaceutical policy
Public: Jul 20, 2026, 9:57 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy. Prescrption drug pricing policy.
Public: Jul 20, 2026, 8:12 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Public: Jul 20, 2026, 5:56 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Legislative and regulatory proposals to change international and domestic corporate tax law and policy. Advocate on domestic and global drug pricing proposals, international trade and protection
Public: Jul 20, 2026, 5:19 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Public: Jul 20, 2026, 2:38 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to regulation of prescription drugs and biologics
Public: Jul 20, 2026, 1:10 PM EDTOriginal source ↗GILD: second_quarter 2026 lobbying report
Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development.
Public: Jul 20, 2026, 12:45 PM EDTOriginal source ↗
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- USAspending
- Collection in progress76 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:27 PM EST
- Federal Register
- Stale — refresh overdue301 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST